-
BioSpecifics Technologies Corp. Provides Update on XIAPEX Launch Progress in EU
Friday, May 20, 2011 - 4:04pm | 114BioSpecifics Technologies Corp. (NASDAQ: BSTC) today provided an update on the launch progress of XIAPEX® (collagenase clostridium histolyticum) in Europe. As reported by BioSpecifics' strategic partner, Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), XIAPEX is now available for sale by Pfizer, Inc...
-
BioSpecifics Technologies Corp. Provides Update on XIAPEX Launch Progress in EU; Available Now in 7 Countries
Friday, May 20, 2011 - 4:01pm | 111BioSpecifics Technologies Corp. (NASDAQ: BSTC) today provided an update on the launch progress of XIAPEX® in Europe. As reported by BioSpecifics' strategic partner, Auxilium Pharmaceuticals, Inc. (NYSE: AUXL), XIAPEX is now available for sale by Pfizer, Inc. (NYSE: PFE) in 7 European countries: the...
-
Cephalon Granted Temporary Restraining Order in AMRIX Patent Litigation
Friday, May 20, 2011 - 2:11pm | 82Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc. (NASDAQ: CEPH), and Eurand, Inc., for a Temporary Restraining Order enjoining Mylan Pharmaceuticals Inc., and Mylan Inc. (NYSE: MYL), from manufacturing, using, offering to sell...
-
Cisco is Far From Dead as Focus Shifts to New Technology
Friday, May 20, 2011 - 12:22pm | 862By Tom Clancy Investors are treating large cap tech like large cap pharma. Both sectors generate tremendous cash flows and are burdened by legacy costs, product obsolescence, and the law of large numbers. Investors have the impression they are losing out to smaller, more nimble, competitors....
-
Pfizer's and Bristol-Myers Squibb's ELIQUIS Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
Friday, May 20, 2011 - 10:43am | 79The European Commission has approved ELIQUIS® in the 27 countries of the European Union for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. This decision marks the first approval for ELIQUIS®, a new oral direct Factor Xa...
-
Morgan Stanley Provided Color on Abbott Laboratories, Overweight
Friday, May 20, 2011 - 8:30am | 142Morgan Stanley provided color on Abbott Laboratories (NYSE: ABT) after an FDA panel discussed the safety of some of its products. In a research report published today, Morgan Stanley states, "An FDA panel convened yesterday to discuss safety data from the ACCORD study of combination fenofibrate/...
-
CHMP Issues Positive Opinion for Merck's VICTRELISTM, Oral Hepatitis C Virus Protease Inhibitor
Friday, May 20, 2011 - 7:35am | 85Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment1 recommending approval of the investigational medicine...
-
A Peek Into The Market Before The Trading Starts
Friday, May 20, 2011 - 7:29am | 401Pre-open movers US stock futures are lower this morning. Futures on the Dow Jones Industrial Average dipped 31 points to 12,560.00 and futures on the S&P 500 stock index fell 3.70 points to 1,338.00. Nasdaq 100 futures dropped 6.25 points to 2,362.75. A Peek Into Global Markets Asian...
-
Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX in EU
Friday, May 20, 2011 - 7:06am | 100Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the Company received a $7.5 million regulatory milestone from Pfizer, Inc. (NYSE: PFE) following the first sale of XIAPEX in Germany, a major EU market. XIAPEX is now available for sale in the United Kingdom, Germany, Denmark,...
-
GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA
Friday, May 20, 2011 - 7:05am | 73GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA as an add-on therapy in adult patients with...
-
Jefferies Lowers PT On Auxilium Pharmaceuticals To $38
Friday, May 20, 2011 - 5:45am | 27Jefferies & Company has lowered the price target on Auxilium Pharmaceuticals (NASDAQ: AUXL) from $39 to $38 and maintains its Buy rating.
-
A Mega Cap ETF Joins the First Trust AlphaDEX Lineup
Thursday, May 19, 2011 - 4:04pm | 560Last month, First Trust introduced a group of 13 new AlphaDEX ETFs. For some reason, the First Trust Mega Cap AlphaDEX Fund (FMK) was not part of that launch. This was corrected last Thursday (5/12/11) with the listing of FMK. The AlphaDEX methodology (pdf) employs a proprietary, rules-based...
-
7 Stocks That Are Breaking Down
Thursday, May 19, 2011 - 3:36pm | 151The stocks below are showing signs of, or already in the process of, breaking down as the smart money appears to be leaving them in a subtle manner. There are stocks trading at its peak and finally showing some vulnerability, while on the other extreme, there are stocks that...
-
Amarin Shares Spiking (AMRN)
Thursday, May 19, 2011 - 3:09pm | 87Amarin (NASDAQ: AMRN) shares began spiking around a half hour ago and are currently up 4.41% to $17.30. The company is providing additional details with regard to its successful MARINE Phase III Trial at the National Lipid Association 2011 Annual Scientific Sessions today. Amarin Corporation plc...
-
Exclusive – Merck Talks To Benzinga About Collaboration With Roche (MRK)
Thursday, May 19, 2011 - 10:50am | 187As reported yesterday, Merck (NYSE: MRK) has entered into agreements with Roche to improve treatment, diagnosis and awareness of chronic hepatitis C infection in developed and emerging markets. Up until now, the two companies have been rivals in the hepatitis C drug market. Both have been selling...